{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-26-000049","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2026-05-13T20:16:30+00:00","discovered_at":"2026-05-13T20:18:00.276681+00:00","generated_at":"2026-05-13T21:55:51.790132+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Praxis reports Q1 net loss of $92.6M; FDA accepts NDAs for ulixacaltamide and relutrigine","bullets":["FDA accepted NDA for ulixacaltamide (Essential Tremor) with PDUFA Jan 29, 2027; relutrigine NDA (SCN2A/SCN8A DEEs) granted priority review with PDUFA Sept 27, 2026.","Cash and investments $1.4B as of Mar 31, 2026, up from $926.1M Dec 2025; funded into 2028.","Net loss $92.6M vs $69.3M in Q1 2025; R&D expenses $78.0M (up $17.2M YoY); G&A $27.9M (up $14.0M YoY).","EMBRAVE Part A: elsunersen showed 77% placebo-adjusted seizure reduction; 71% patients achieved >50% reduction.","Topline POWER1 (vormatrigine in FOS) expected Q2 2026; EMERALD (relutrigine in broad DEEs) topline Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-26-000049","json":"https://secwatch.observer/filing/0001689548-26-000049.json","markdown":"https://secwatch.observer/filing/0001689548-26-000049.md","text":"https://secwatch.observer/filing/0001689548-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/0001689548-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/prax-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:55:51.790132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}